AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15930482 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline and Carnitine supplementation
Number of subjects: 19
Study 15930482 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 19
Study 12795789 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation
Number of subjects: 30
Study 12795789 — intervention group
Group type: COMPARATOR
Intervention: Hand instrumentation (scaling and root planing - SRP)
Number of subjects: 30
Study 10513801 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 0
Study 10513801 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 8588058 — intervention group
Group type: COMPARATOR
Intervention: Trimipramine alone 200 mg/d (group 1)
Number of subjects: 18
Study 8588058 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimipramine (200 mg/d) and additional serial partial sleep deprivation (3x/week) (group 2)
Number of subjects: 18
Study 8588058 — intervention group
Group type: COMPARATOR
Intervention: Control (group 1)
Number of subjects: 18
Study 8588058 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental (group 2)
Number of subjects: 18
Study 2048453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (before or after drinking)
Number of subjects: 0
Study 2048453 — intervention group
Group type: COMPARATOR
Intervention: Sugarless gum (control)
Number of subjects: 0
Study 2048453 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (after chewing gum)
Number of subjects: 0
Study 2048453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (side effects)
Number of subjects: 0
Study 2048453 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and historical variables
Number of subjects: 0
Study 6165205 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% budesonide ointment
Number of subjects: 116
Study 6165205 — intervention group
Group type: COMPARATOR
Intervention: 0.025% fluocinolone acetonide ointment
Number of subjects: 116
Study 6165205 — intervention group
Group type: COMPARATOR
Intervention: 0.010% budesonide ointment
Number of subjects: 116
Study 31747132 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitors (empagliflozin and canagliflozin)
Number of subjects: 139317
Study 31747132 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA-eligible patients
Number of subjects: 139317
Study 30111333 — intervention group
Group type: EXPERIMENTAL
Intervention: F@ce™ intervention (8-week family-centred intervention with goal setting, problem-solving strategies, daily reminders, and self-rated follow-ups via SMS)
Number of subjects: 28
Study 30111333 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study 27394383 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention (10 in-home occupational therapy visits, 1 in-home visit, and 1 telephone contact by an advanced practice nurse)
Number of subjects: 0
Study 27394383 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE intervention
Number of subjects: 0
Study 27394383 — intervention group
Group type: COMPARATOR
Intervention: Ongoing CHCPE services only
Number of subjects: 0
Study 23942200 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics e‐learning Continuing Professional Development (CPD) module
Number of subjects: 80
Study 23942200 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 27552780 — intervention group
Group type: EXPERIMENTAL
Intervention: Email plus text messaging for 12 weeks
Number of subjects: 0
Study 27552780 — intervention group
Group type: COMPARATOR
Intervention: Email only
Number of subjects: 0
Study 19484170 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly for 8 weeks
Number of subjects: 78
Study 19484170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 18787216 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg twice daily)
Number of subjects: 30
Study 18787216 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg once daily)
Number of subjects: 30
Study 18787216 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid (300 mg daily)
Number of subjects: 30
Study 16234222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense exercise
Number of subjects: 28
Study 16234222 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 28
Study 14507557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheoscopy
Number of subjects: 26
Study 12119985 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 12119985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8884013 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey dressing
Number of subjects: 100
Study 8884013 — intervention group
Group type: COMPARATOR
Intervention: Boiled potato peel dressing
Number of subjects: 100
Study 1395117 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 3878441 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid alone
Number of subjects: 0
Study 3878441 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid with caffeine
Number of subjects: 0
Study 3878441 — intervention group
Group type: COMPARATOR
Intervention: Tolfenamic acid with placebo
Number of subjects: 0
Study 29175066 — intervention group
Group type: EXPERIMENTAL
Intervention: EmbryoScope (TLI)
Number of subjects: 386
Study 29175066 — intervention group
Group type: COMPARATOR
Intervention: G185 K-System (G185)
Number of subjects: 386
Study 27569734 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 99
Study 27569734 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil plus midazolam
Number of subjects: 99
Study 27569734 — intervention group
Group type: COMPARATOR
Intervention: Meperidine/midazolam
Number of subjects: 99
Study 24690891 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 4 ml/kg
Number of subjects: 39
Study 24690891 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume of 6 ml/kg
Number of subjects: 39
Study 24690891 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume of 8 ml/kg
Number of subjects: 39
Study 24690891 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 39
Study 22417569 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated and humidified high-flow oxygen therapy (HHFO₂)
Number of subjects: 30
Study 22417569 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy (no humidification)
Number of subjects: 30
Study 20618242 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacca Re‐Usable Omnicup
Number of subjects: 200
Study 20618242 — intervention group
Group type: COMPARATOR
Intervention: Bird anterior and posterior metal cups
Number of subjects: 200
Study 18762033 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin cement (2bond2)
Number of subjects: 128
Study 18762033 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer cement (Ketac Cem)
Number of subjects: 128
Study 18762033 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal thickness of 0.5 mm
Number of subjects: 128
Study 18762033 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal thickness of 1.3 mm
Number of subjects: 128
Study 18762033 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamfer finish line
Number of subjects: 128
Study 18762033 — intervention group
Group type: COMPARATOR
Intervention: Shoulder finish line
Number of subjects: 128
Study 18762033 — intervention group
Group type: EXPERIMENTAL
Intervention: Total convergence angle of 4 degrees
Number of subjects: 128
Study 18762033 — intervention group
Group type: COMPARATOR
Intervention: Total convergence angle of 11 degrees
Number of subjects: 128
Study 15800921 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-fiber diet (LFHF)
Number of subjects: 154
Study 15800921 — intervention group
Group type: COMPARATOR
Intervention: Soy supplement with isoflavones (soy+IF)
Number of subjects: 154
Study 15800921 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplement (both soy+IF and soy-IF)
Number of subjects: 154
Study 12867777 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Heart Failure Questionnaire (CHQ)
Number of subjects: 211
Study 12867777 — intervention group
Group type: EXPERIMENTAL
Intervention: Minnesota Living with Heart Failure Questionnaire (LHFQ)
Number of subjects: 211
Study 12867777 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Survey Short-form-12 (SF-12)
Number of subjects: 211
Study 12867777 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interviews
Number of subjects: 211
Study 12867777 — intervention group
Group type: COMPARATOR
Intervention: Telephone interviews
Number of subjects: 211
Study 10588212 — intervention group
Group type: EXPERIMENTAL
Intervention: High endotoxin levels (beyond 50 pg/ml)
Number of subjects: 516
Study 10588212 — intervention group
Group type: EXPERIMENTAL
Intervention: High endotoxin levels
Number of subjects: 516
Study 10588212 — intervention group
Group type: COMPARATOR
Intervention: Low endotoxin levels in smokers
Number of subjects: 516
Study 10588212 — intervention group
Group type: EXPERIMENTAL
Intervention: High endotoxin levels in smokers
Number of subjects: 516
Study 8954302 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA analysis for expanded trinucleotide (CAG) repeat sequence in the IT15 gene
Number of subjects: 27
Study 1772813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet application (varied by width and inflation pressure)
Number of subjects: 12
Study 1772813 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet application (maintenance of inflation)
Number of subjects: 12
Study 7047002 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus 'triple‐treatment' (vitamin D2 45000 iu twice weekly, sodium fluoride 50 mg and calcium phosphate 4.5 g daily)
Number of subjects: 31
Study 7047002 — intervention group
Group type: COMPARATOR
Intervention: Prednisone only (Control)
Number of subjects: 31
Study 31868983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 2 L/min
Number of subjects: 16
Study 31868983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 4 L/min
Number of subjects: 16
Study 31868983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 6 L/min
Number of subjects: 16
Study 31868983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high flow (NHF) at 8 L/min
Number of subjects: 16
Study 29924955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus sodium thiosulfate (20 g/m² intravenously over 15 minutes, 6 hours after cisplatin)
Number of subjects: 109
Study 29924955 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone (80 mg/m² over 6 hours)
Number of subjects: 109
Study 29924955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus sodium thiosulfate
Number of subjects: 109
Study 29924955 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 109
Study 26971473 — intervention group
Group type: EXPERIMENTAL
Intervention: Active E‐NFT
Number of subjects: 25
Study 26971473 — intervention group
Group type: COMPARATOR
Intervention: Sham E‐NFT
Number of subjects: 25
Study 24525469 — intervention group
Group type: EXPERIMENTAL
Intervention: RPV/FTC/TDF
Number of subjects: 786
Study 24525469 — intervention group
Group type: COMPARATOR
Intervention: EFV/FTC/TDF
Number of subjects: 786
Study 22335299 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac Nano (KN)
Number of subjects: 60
Study 22335299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Filling LC (FF)
Number of subjects: 60
Study 22335299 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji II LC (FII)
Number of subjects: 60
Study 22335299 — intervention group
Group type: COMPARATOR
Intervention: Fuji II LC without light cure (FII woLC)
Number of subjects: 60
Study 22335299 — intervention group
Group type: COMPARATOR
Intervention: Fuji Filling LC without light cure (FF woLC)
Number of subjects: 60
Study 22335299 — intervention group
Group type: COMPARATOR
Intervention: Ketac Nano without light cure (KN woLC)
Number of subjects: 60
Study 21351399 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative coiling of the AAA sac (Group A)
Number of subjects: 86
Study 21351399 — intervention group
Group type: COMPARATOR
Intervention: No coiling of the AAA sac (Group B)
Number of subjects: 86
Study 18051002 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin adhesive (Seal & Protect) applied to coated teeth
Number of subjects: 19
Study 18051002 — intervention group
Group type: COMPARATOR
Intervention: Control (uncoated teeth)
Number of subjects: 19
Study 18051002 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin adhesive (Seal & Protect)
Number of subjects: 19
Study 16289797 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Intervention Strategy (MIS)
Number of subjects: 314
Study 16289797 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 314
Study 12243243 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan B gel dressing
Number of subjects: 20
Study 12243243 — intervention group
Group type: COMPARATOR
Intervention: Control (no gel dressing)
Number of subjects: 20
Study 10576139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial meningitis group (n=18)
Number of subjects: 18
Study 10576139 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=18)
Number of subjects: 18
Study 8549224 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous heparin (SCH) 5,000 U every 12 hours
Number of subjects: 2551
Study 8549224 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of pneumatic compression stockings (PCS) and subcutaneous heparin (SCH)
Number of subjects: 2551
Study 1986565 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (angiotensin I converting enzyme inhibitor)
Number of subjects: 27
Study 1986565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6134626 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal suspension (50 g charcoal)
Number of subjects: 6
Study 6134626 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup of ipecac
Number of subjects: 6
Study 6134626 — intervention group
Group type: COMPARATOR
Intervention: Water (300 ml)
Number of subjects: 6
Study 6134626 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal vs. ipecac
Number of subjects: 6
Study 31201785 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin treatment for 28 days
Number of subjects: 40
Study 30053620 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow diversion (FD)
Number of subjects: 40
Study 30053620 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 40
Study 30053620 — intervention group
Group type: COMPARATOR
Intervention: Surgical group (bypass)
Number of subjects: 40
Study 30053620 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow diversion (FD) and Bypass surgery
Number of subjects: 40
Study 27062084 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby-friendly Initiative (BFI) in community health services
Number of subjects: 3948
Study 27062084 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 3948
Study 25065668 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20mg/day) followed by Lapatinib (1500mg/day) after 28 days
Number of subjects: 25
Study 25065668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1500mg/day) followed by Tamoxifen (20mg/day) after 14 days
Number of subjects: 25
Study 22301368 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents with biodegradable polymer
Number of subjects: 1161
Study 22301368 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 1161
Study 21058129 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 52
Study 21058129 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 52
Study 16761216 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training program (12 weeks, 2 sessions per week, increasing to 4 sessions per week)
Number of subjects: 24
Study 16761216 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study 15896352 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 20 mg
Number of subjects: 53
Study 15896352 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 53
Study 15896352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 12169931 — intervention group
Group type: EXPERIMENTAL
Intervention: TBOPP program
Number of subjects: 132
Study 12169931 — intervention group
Group type: COMPARATOR
Intervention: noTBOPP group
Number of subjects: 132
Study 11338314 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for hypertension
Number of subjects: 2301
Study 11338314 — intervention group
Group type: COMPARATOR
Intervention: Untreated candidates for drug treatment
Number of subjects: 2301
Study 9544892 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids (budesonide or beclomethasone)
Number of subjects: 56
Study 9544892 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (non-steroid treated)
Number of subjects: 56
Study 8290193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketorolac (60 mg)
Number of subjects: 84
Study 8290193 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (100 micrograms at induction, 25 micrograms boluses after 45 and 90 minutes)
Number of subjects: 84
Study 8290193 — intervention group
Group type: COMPARATOR
Intervention: Oral piroxicam (40 mg)
Number of subjects: 84
Study 2691141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (short-term, 2 weeks)
Number of subjects: 576
Study 2691141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (long-term, 12-52 months)
Number of subjects: 576
Study 2691141 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (in patients with cardiac failure)
Number of subjects: 576
Study 2691141 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 576
Study 2691141 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 576
Study 46049 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 68
Study 46049 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 68
Study 6985729 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU + Mito C (20 mg/m2 IV bolus every 8 weeks)
Number of subjects: 57
Study 6985729 — intervention group
Group type: COMPARATOR
Intervention: 5FU + MeCCNU (150 mg/m2 orally every 8 weeks)
Number of subjects: 57
Study 30665229 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-foot exercise (SFE)
Number of subjects: 30
Study 30665229 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive sensory exercise (PSE)
Number of subjects: 30
Study 30203746 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of zoledronic acid combined with oral medication of cinobufagin
Number of subjects: 120
Study 30203746 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of zoledronic acid
Number of subjects: 120
Study 26537183 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 18
Study 26537183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 24976202 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole and antiepileptics
Number of subjects: 123
Study 24976202 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptics only (Control)
Number of subjects: 123
Study 22585886 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR use
Number of subjects: 798
Study 22585886 — intervention group
Group type: COMPARATOR
Intervention: Non-EHR use (Control)
Number of subjects: 798
Study 20814335 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 57
Study 20814335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 20814335 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (2000 mg)
Number of subjects: 57
Study 17654600 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta-1a
Number of subjects: 257
Study 17654600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 17654600 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta-1a plus ribavirin
Number of subjects: 257
Study 16038841 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT) for 20 min, once a day, 5 days a week, over a period of 3 weeks
Number of subjects: 61
Study 16038841 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT) + 1000 mg naproxen (NSAID)
Number of subjects: 61
Study 16038841 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg naproxen (NSAID)
Number of subjects: 61
Study 16038841 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (BT)
Number of subjects: 61
Study 11815495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1439
Study 11815495 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1439
Study 11815495 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon and evening plasma glucose measurements
Number of subjects: 1439
Study 9873161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-55 (55Co) positron emission tomography (PET) tracer
Number of subjects: 0
Study 7853167 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-31260 (3, 15, 30, 60, 100, and 200 mg)
Number of subjects: 18
Study 7853167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7853167 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-31260 (60-200 mg)
Number of subjects: 18
Study 7853167 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-31260 (100 and 200 mg)
Number of subjects: 18
Study 7853167 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-31260 (200 mg)
Number of subjects: 18
Study 1955232 — intervention group
Group type: EXPERIMENTAL
Intervention: levamisole 5 mg/kg body weight on 3 consecutive days every 2 weeks for a period up to 5 months
Number of subjects: 40
Study 1955232 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40